Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 3/1999

01-05-1999

CD44s-targeted treatment with monoclonal antibody blocks intracerebral invasion and growth of 9L gliosarcoma

Authors: Sven Gunia, Sami Hussein, Dorel L. Radu, Klaus-Martin Pütz, Roger Breyer, Hartmut Hecker, Madjid Samii, Gerhard F. Walter, Alexandru C. Stan

Published in: Clinical & Experimental Metastasis | Issue 3/1999

Login to get access
Metadata
Title
CD44s-targeted treatment with monoclonal antibody blocks intracerebral invasion and growth of 9L gliosarcoma
Authors
Sven Gunia
Sami Hussein
Dorel L. Radu
Klaus-Martin Pütz
Roger Breyer
Hartmut Hecker
Madjid Samii
Gerhard F. Walter
Alexandru C. Stan
Publication date
01-05-1999
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 3/1999
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1006699203287

Other articles of this Issue 3/1999

Clinical & Experimental Metastasis 3/1999 Go to the issue

OriginalPaper

Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR)

OriginalPaper

Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection

OriginalPaper

Enhanced inhibition of experimental metastasis by the combination chemotherapy of Cu-Zn SOD and adriamycin

OriginalPaper

LCC15-MB: a vimentin-positive human breast cancer cell line from a femoral bone metastasis

OriginalPaper

Human breast cancer cells activate procollagenase-1 and invade type I collagen: invasion is inhibited by all-trans retinoic acid

OriginalPaper

Evidence for tumor-host cooperation in regulating MMP-2 expression in human colon cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits